Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02861209
Other study ID # LMK15022016
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 2015
Est. completion date November 2022

Study information

Verified date April 2019
Source KU Leuven
Contact Lise-Marie Kinnaer, PharmD
Phone 3216328265
Email lisemarie.kinnaer@kuleuven.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD).

The care pathway will be developed in six hospitals in Flanders, and will be adapted to the local setting and situation.

The investigators hypothesize that the implementation of a care pathway will increase the quality of the drug therapy, the communication between health care professionals (HCPs) and patients, and will lead to an improved level of self-management and adherence. Moreover, the invesitgators hypothesize that the care pathway will facilitate the communication between HCPs in the hospital setting and in ambulatory care, and will improve counseling skills, self-efficacy and self-confidence of HCPs.

At the end of the study, a roadmap for the nation-wide implementation of a similar care pathway will be constructed based on the experiences of the participating hospitals. This roadmap will certainly include an e-learning platform for healthcare professionals.


Description:

For each hospital, an individual care pathway will be developed following the 7-phase model by Vanhaecht et al., 2011. This methodology aims to offer a systematic approach in 7 phases for the support of an interdisciplinary team in the development of new care pathways or in the improvement of existing ones.

The before-part of the study includes phases 1 to 4 that aim to map current practice in detail and to translate these findings into the development of a care pathway. Current practice will be investigated using mixed methods comprising:

- surveys evaluating care on the level of the hospital

- semi-structured interviews with healthcare professionals (HCP) and patients

- outcome assessments in patients included in the study (self-management, adherence, satisfaction with care, satisfaction with information, quality of life) using validated questionnaires at the start of the therapy, after 1 month and after three months

- outcome assessments in healthcare professionals at baseline (self-efficacy and perceptions on self-management) using validated questionnaires

- training and feedback sessions on counseling for HCPs

Based upon these findings, a care pathway in each hospital will be developed by a local project team of different stakeholders from different disciplines.

The after-part of the study includes phase 5-7 in which the care pathway is implemented, evaluated and continuously followed up.

Implementation and evaluation take place at the same time. The evaluation includes:

- outcome assessments in patients (newly recruited) at the start of the therapy, after 1 month and after three months

- outcome assessments in HCPs (follow up)

- evaluation of counseling skills

- focus group discussions and interviews with HCPs to evaluate the development and implementation of the care pathway.

At the end of the study a comparison of outcomes before and after the implementation will be made to study the impact of the care pathway on the before mentioned aspects (see "Brief Summary").


Recruitment information / eligibility

Status Recruiting
Enrollment 228
Est. completion date November 2022
Est. primary completion date November 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- a hematological cancer of solid tumor

- starting an oral anticancer drug for the first time

- able to understand and speak Dutch

Exclusion Criteria:

- patients following an adjuvant oral anticancer therapy (e.g. tamoxifen)

- patients following a therapy with a study drug

Study Design


Intervention

Other:
Implementation of a care pathway
The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.

Locations

Country Name City State
Belgium Imelda Bonheiden Bonheiden Vlaams-Brabant
Belgium Maria Middelares Gent Ghent Oost-Vlaanderen
Belgium AZ Groeninge Kortrijk Kortrijk West-Vlaanderen
Belgium AZ Turnhout Turnhout Antwerpen

Sponsors (1)

Lead Sponsor Collaborator
KU Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Self-efficacy in HCPs using the Self-efficacy and Performance in Self-management Instrument (SEPSS) SEPSS investigates the ability of a HCP to evaluate their own performance in daily practice and caregiving. at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
Other Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
Primary Change in self-management skills There is no gold standard to define self-management. A definition from Barlow et al., 2002 (2) defines self-management as follows: the ability of an individual to manage the symptoms, treatment, physical and psychosocial consequences and life style changes due to his/her condition. Adequate self-management refers to the ability to monitor one's condition and to effect cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality of life.
The studied self-management skills in this project comprise "social integration and support", "health service navigation", "constructive attitudes and approaches", "skill and technique acquisition" and "emotional distress".
at the start of the therapy, after one and three months
Secondary Change in medication Adherence after one and three months of therapy
Secondary Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ) after one and three months
Secondary Change in patient satisfaction with care using Out-patsat 35 The outpatsat is a questionnaire for ambulatory cancer patients in which they are asked to rate in different subscales their perceptions on care delivered by doctors, nurses and rate te overall organisation (accessibility of the hospital, ease of reaching the hospital by telephone, ...) during their stay at day hospital of consultations at the start of the therapy, after one and three months
Secondary Health Related Quality of Life at the start of the therapy, after one and three months
Secondary Change in Distress using the Distress Barometer at the start of the therapy, after one and three months
Secondary Efficacy of treatment Using ECOG performance scale and RECIST criteria at the start of the therapy, after one and three months
Secondary Toxicity of treatment Summarizing adverse drug events at the start of the therapy, after one and three months
Secondary Cost of care Prospective report on health care expenditures (use of healthcare and other services, use of medicines, …) at the start of the therapy, after one and three months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A